AIDS and Behavior

, Volume 10, Issue 3, pp 227–245 | Cite as

Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management

  • Jane M. Simoni
  • Ann E. Kurth
  • Cynthia R. Pearson
  • David W. Pantalone
  • Joseph O. Merrill
  • Pamela A. Frick
Original Article

Abstract

A review of 77 studies employing self-report measures of antiretroviral adherence published 1/1996 through 8/2004 revealed great variety in adherence assessment item content, format, and response options. Recall periods ranged from 2 to 365 days (mode=7 days). The most common cutoff for optimal adherence was 100% (21/48 studies, or 44%). In 27 of 34 recall periods (79%), self-reported adherence was associated with adherence as assessed with other indirect measures. Data from 57 of 67 recall periods (84%) indicated self-reported adherence was significantly associated with HIV-1 RNA viral load; in 16 of 26 (62%), it was associated with CD4 count. Clearly, the field would benefit from item standardization and a priori definitions and operationalizations of adherence. We conclude that even brief self-report measures of antiretroviral adherence can be robust, and recommend items and strategies for HIV research and clinical management.

Keywords

HIV/AIDS Antiretroviral Medication adherence Self-report Viral load 

References (Numbered asterisks indicate studies cited in Fig. 1)

  1. Alcoba, M., Cuevas, M. J., Perez-Simon, M. R., Mostaza, J. L., Ortega, L., Ortiz de Urbina, J., et al. (2003). Assessment of adherence to triple antiretroviral treatment including indinavir: Role of the determination of plasma levels of indinavir. Journal of Acquired Immune Deficiency Syndromes, 33(2), 253–258.PubMedGoogle Scholar
  2. Aloisi, M. S., Arici, C., Balzano, R., Noto, P., Piscopo, R., Filice, G., et al. (2002). Behavioral correlates of adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl 3), S145–S148.PubMedGoogle Scholar
  3. Altice, F. L., Mostashari, F., and Friedland, G. H. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 28(1), 47–58.PubMedGoogle Scholar
  4. Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., Bartoli, L., et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45(5), 394–402.PubMedGoogle Scholar
  5. Antinori, A., Cozzi-Lepri, A., Ammassari, A., Trotta, M. P., Nauwelaers, D., Hoetelmans, R., et al. (2004). Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antiviral Therapy, 9(2), 291–296.PubMedGoogle Scholar
  6. Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33(8), 1417–1423.PubMedGoogle Scholar
  7. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357–366.PubMedGoogle Scholar
  8. Bangsberg, D. R., Bronstone, A., and Hofmann, R. (2002). A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care, 14(1), 3–15.PubMedGoogle Scholar
  9. Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., et al. (2003). High levels of adherence do not prevent accumulation of HIV drug resistanc mutations. AIDS, 17(13), 1925–1932.PubMedGoogle Scholar
  10. Bangsberg, D. R., Hecht, F. M., Clague, H., Charlebois, E. D., Ciccarone, D., Chesney, M., et al. (2001). Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26(5), 435–442.PubMedGoogle Scholar
  11. Bangsberg, D. R., Moss, A. R., and Deeks, S. G. (2004). Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 53(5), 696–699.PubMedGoogle Scholar
  12. Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., et al. (2003). High levels of adherence do not prevent accumulation of HIV drug resistant mutations. AIDS, 17, 1925–1932.PubMedGoogle Scholar
  13. Barroso, P. F., Schechter, M., Gupta, P., Bressan, C., Bomfim, A., and Harrison, L. H. (2003). Adherence to antiretroviral therapy and persistence of HIV RNA in semen. Journal of Acquired Immune Deficiency Syndromes, 32(4), 435–440.PubMedGoogle Scholar
  14. Bartlett, J. A. (2002). Addressing the challenges of adherence. Journal of Acquired Immune Deficiency Syndromes, 29(Suppl 1), S2–S10.PubMedGoogle Scholar
  15. Bartlett, J. G., and Gallant, J. E. (2004). Medical management of HIV infection (2004 ed.). Baltimore, MD: Johns Hopkins Medicine Health Publishing Business Group.Google Scholar
  16. Bova, C. A., Fennie, K. P., Knafl, G. J., Dieckhaus, K. D., Watrous, E., and Williams, A. B. (2005). Use of electronic monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS and Behavior, 9(1), 103–110.PubMedGoogle Scholar
  17. Brigido, L. F., Rodrigues, R., Casseb, J., Oliveira, D., Rossetti, M., Menezes, P., et al. (2001). Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care and STDS, 15(11), 587–593.PubMedGoogle Scholar
  18. Caplan, R. D., Harrison, R. V., Wellons, R. V., and Frech, J. R. P. (1980). Social support and patient adherence: Experimental and survey findings. Ann Arbor, MI: Survey Research Center, University of Michigan.Google Scholar
  19. Carrieri, P., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., Bouvet, E., et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndromes, 28(3), 232–239.PubMedGoogle Scholar
  20. Carrieri, M. P., Raffi, F., Lewden, C., Sobel, A., Michelet, C., Cailleton, V., et al. (2003). Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: A 3-year follow-up study. Antiviral Therapy, 8(6), 585–594.PubMedGoogle Scholar
  21. Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., and McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19(2), 124–133.PubMedGoogle Scholar
  22. Cederfjall, C., Langius-Eklof, A., Lidman, K., and Wredling, R. (2002). Self-reported adherence to antiretroviral treatment and degree of sense of coherence in a group of HIV-infected patients. AIDS Patient Care and STDS, 16(12), 609–616.PubMedGoogle Scholar
  23. Cingolani, A., Antinori, A., Rizzo, M. G., Murri, R., Ammassari, A., Baldini, F., et al. (2002). Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS, 16(3), 369–379.PubMedGoogle Scholar
  24. Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12(3), 255–266.PubMedGoogle Scholar
  25. Cohn, S. E., Kammann, E., Williams, P., Currier, J. S., and Chesney, M. A. (2002). Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in acquired immunodeficiency syndrome. Clinical Infectious Diseases, 34(8), 1129–1136.PubMedGoogle Scholar
  26. DiMatteo, M. R. (2004). Variations in patients’ adherence to medical recommendations: A quantitative review of 50 years of research. Medical Care, 42(3), 200–209.PubMedGoogle Scholar
  27. Dorz, S., Lazzarini, L., Cattelan, A., Meneghetti, F., Novara, C., Concia, E., et al. (2003). Evaluation of adherence to antiretroviral therapy in Italian HIV patients. AIDS Patient Care and STDs, 17(1),33.PubMedGoogle Scholar
  28. Duong, M., Piroth, L., Peytavin, G., Forte, F., Kohli, E., Grappin, M., et al. (2001). Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response. Clinical Infectious Diseases, 33(3), 386–392.PubMedGoogle Scholar
  29. Duran, S., Peytavin, G., Carrieri, P., Raffi, F., Ecobichon, J. L., Pereira, E., et al. (2003). The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. AIDS, 17(7), 1096–1099.PubMedGoogle Scholar
  30. Duran, S., Saves, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., et al. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 15(18), 2441–2444.PubMedGoogle Scholar
  31. Duran, S., Solas, C., Spire, B., Carrieri, M. P., Fuzibet, J. G., Costagliola, D., et al. (2001). ‘Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?’ A comparison between patients’ self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS, 15(8), 1075–1077.PubMedGoogle Scholar
  32. Eldred, L., Wu, A., Chaisson, R., and Moore, R. (1998). Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18(2), 117–125.PubMedGoogle Scholar
  33. Fong, O. W., Ho, C. F., Fung, L. Y., Lee, F. K., Tse, W. H., Yuen, C. Y., et al. (2003). Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Medicine, 4(2), 133–138.PubMedGoogle Scholar
  34. Gao, X., Nau, D., Rosenbluth, S., Scott, V., and Woodward, C. (2000). The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care, 12(4), 387–398.PubMedGoogle Scholar
  35. Garcia de Olalla, P., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J. L., and Cayla, J. A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 30, 105–110.PubMedGoogle Scholar
  36. Geletko, S. M., Segarra, M., Mayer, K. H., Fiore, T. C., Bettencourt, F. A., Flanigan, T. P., et al. (1996). Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Antimicrobial Agents and Chemotherapy, 40(6), 1338–1341.PubMedGoogle Scholar
  37. Gifford, A., Bormann, J., Shively, M., Wright, B., Richman, D., and Bozzette, S. (2000). Predictors of self-reported adherence and plasma HIV concentrates in patients on multi drug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 23(5), 386–395.PubMedGoogle Scholar
  38. Giordano, T. P., Guzman, D., Clark, R., Charlebois, E. D., and Bangsberg, D. R. (2004). Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clinical Trials, 5(2), 74–79.PubMedGoogle Scholar
  39. Godin, G., Gagne, C., and Naccache, H. (2003). Validation of a self-reported questionnaire assessing adherence to antiretroviral medication. AIDS Patient Care and STDs, 17(7), 325.PubMedGoogle Scholar
  40. Golin, C. E., Liu, H., Hays, R. D., Miller, L. G., Beck, C. K., Ickovics, J., et al. (2002). A prospective study of predictors of adherence to combination antiretroviral medication. Journal of General Internal Medicine, 17(10), 756–765.PubMedGoogle Scholar
  41. Gordillo, V., del Amo, J., Soriano, V., and Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13(13), 1763–1769.PubMedGoogle Scholar
  42. Gordis, L. (1979). Conceptual and methodologic problems in measuring patient compliance. In D. W. T. R. B. Haynes and D. L. Sackett (Eds.), Compliance in health care (pp. 23–48). Baltimore, MD: Johns Hopkins University.Google Scholar
  43. Goujard, C., Bernard, N., Sohier, N., Peyramond, D., Lançon, F., Chwalow, J., et al. (2003). Impact of a patient education program on adherence to HIV medication: A randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes, 34(2), 191–194.PubMedGoogle Scholar
  44. Grossberg, R., Zhang, Y., and Gross, R. (2004). A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. Journal of Clinical Epidemiology, 57(10), 1107–1110.PubMedGoogle Scholar
  45. Haubrich, R. H., Little, S. J., Currier, J. S., Forthal, D. N., Kemper, C. A., Beall, G. N., et al. (1999). The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS, 13, 1099–1107.PubMedGoogle Scholar
  46. Ho, C. F., Fong, O. W., and Wong, K. H. (2002). Patient self-report as a marker of adherence to antiretroviral therapy. Clinical Infectious Diseases, 34(11), 1534–1535.PubMedGoogle Scholar
  47. Hogg, R., Heath, K., Bangsberg, D. R., Yip, B., Press, N., O'shaughnessy, M. V., et al. (2002). Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS, 16, 1051–1058.Google Scholar
  48. Horne, R., Buick, D., Fisher, M., Leake, H., Cooper, V., and Weinman, J. (2004). Doubts about necessity and concerns about adverse effects: Identifying the types of beliefs that are associated with non-adherence to HAART. International Journal of STD AIDS, 15(1), 38–44.PubMedGoogle Scholar
  49. Hugen, P. W., Langebeek, N., Burger, D. M., Zomer, B., van Leusen, R., Schuurman, R., et al. (2002). Assessment of adherence to HIV protease inhibitors: Comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndromes, 30(3), 324–334.PubMedGoogle Scholar
  50. Ickovics, J. (1997). Measures of adhference. Paper presented at the Adherence to New HIV Therapies: A Research Conference, Washington, DC..Google Scholar
  51. Ickovics, J. R., Cameron, A., Zackin, R., Bassett, R., Chesney, M., Johnson, V. A., et al. (2002). Consequences and determinants of adherence to antiretroviral medication: Results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Therapy, 7(3), 185–193.PubMedGoogle Scholar
  52. Ingersoll, K. (2004). The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care, 16(2), 199–211.PubMedGoogle Scholar
  53. Kimmerling, M., Wagner, G., and Ghosh-Dastidar, B. (2003). Factors associated with accurate self-reported adherence to HIV antiretrovirals. International Journal of STD AIDS, 14(4), 281–284.PubMedGoogle Scholar
  54. Kleeberger, C. A., Phair, J. P., Strathdee, S. A., Detels, R., Kingsley, L., and Jacobson, L. P. (2001). Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 26(1), 82–92.PubMedGoogle Scholar
  55. Kitahata, M. M., Reed, S. D., Dillingham, P. W., Van Rompaey, S. E., Young, A. A., Harrington, R. D., et al. (2004). Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. International Journal of STD AIDS, 15(12), 803–810.PubMedGoogle Scholar
  56. Knobel, H., Alonso, J., Casado, J., Collazos, J., Gonzalez, J., Ruiz, I., et al. (2002). Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS, 16, 605–613.PubMedGoogle Scholar
  57. Knobel, H., Guelar, A., Carmona, A., Espona, M., Gonzalez, A., Lopez-Colomes, J. L., et al. (2001). Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care and STDs, 15, 193–199.PubMedGoogle Scholar
  58. Knobel, H., Vallecillo, G., Guelar, A., Pedrol, E., Soler, A., Carmona, A., et al. (2004). Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients. HIV Clinical Trials, 5(2), 65–73.PubMedGoogle Scholar
  59. Konkle-Parker, D. J. (2000). What is the best way to measure medication adherence? HIV Clinical Trials, 12(3), 11–12.Google Scholar
  60. Laniece, I., Ciss, M., Desclaux, A., Diop, K., Mbodj, F., Ndiaye, B., et al. (2003). Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS, 17(Suppl 3), S103–S108.PubMedCrossRefGoogle Scholar
  61. Le Moing, V., Chene, G., Carrieri, M. P., Alioum, A., Brun-Vezinet, F., Piroth, L., et al. (2002). Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS, 16(1), 21–29.PubMedGoogle Scholar
  62. Le Moing, V., Chene, G., Carrieri, M. P., Besnier, J. M., Masquelier, B., Salamon, R., et al. (2001). Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. Journal of Acquired Immune Deficiency Syndromes, 27(4), 372–376.PubMedGoogle Scholar
  63. Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968–977.PubMedGoogle Scholar
  64. Lucas, G. M., Cheever, L. W., Chaisson, R. E., and Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27(3), 251–259.PubMedGoogle Scholar
  65. Lopez-Suarez, A., Fernandez-Gutierrez del Almo, C., Perez-Guzman, E., and Giron-Gonzalez, J. A. (1998). Adherence to the antiretroviral treatment in asymptomatic HIV-infected patients. AIDS, 12(6), 685–686.PubMedGoogle Scholar
  66. Maggiolo, F., Ripamonti, D., Arici, C., Gregis, G., Quinzan, G., Camacho, G. A., et al. (2002). Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clinical Trials, 3(5), 371–378.PubMedGoogle Scholar
  67. Mannheimer, S., Friedland, G., Matts, J., Child, C., and Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115–1121.PubMedGoogle Scholar
  68. Martin, J., Sabugal, G. M., Rubio, R., Sainz-Maza, M., Blanco, J. M., Alonso, J. L., et al. (2001). Outcomes of a health education intervention in a sample of patients infected by HIV, most of them injection drug users: Possibilities and limitations. AIDS Care, 13(4), 467–473.PubMedGoogle Scholar
  69. Martin-Fernandez, J., Escobar-Rodriguez, I., Campo-Angora, M., and Rubio-Garcia, R. (2001). Evaluation of adherence to highly active antiretroviral therapy. Archives of Internal Medicine, 161(22), 2739–2740.PubMedGoogle Scholar
  70. Martin, J., Sabugal, G. M., Rubio, R., Sainz-Maza, M., Blanco, J. M., Alonso, J. L., et al. (2001). Outcomes of a health education intervention in a sample of patients infected by HIV, most of them injection drug users: Possibilities and limitations. AIDS Care, 13(4), 467–473.PubMedGoogle Scholar
  71. Mathews, W. C., Mar-Tang, M., Ballard, C., Colwell, B., Abulhosn, K., Noonan, C., et al. (2002). Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care and STDS, 16(4), 157–172.PubMedGoogle Scholar
  72. Melbourne, K. M., Geletko, S. M., Brown, S. L., Willey-Lessne, C., Chase, S., and Fisher, A. (1999). Medication adherence in patients with HIV infection: A comparison of two measurement methods. The AIDS Reader, 9(5), 329–338.PubMedGoogle Scholar
  73. Miller, L. G., and Hays, R. D. (2000). Adherence to combination antiretroviral therapy: Synthesis of the literature and clinical implications. The AIDS Reader, 10(3), 177–185.PubMedGoogle Scholar
  74. Miller, L. G., Hays, R. D. (2000). Measuring adherence to antiretroviral medications in clinical trials. HIV Clinical Trials, 1(1), 36–46.PubMedGoogle Scholar
  75. Moatti, J. P., Carrieri, M. P., Spire, B., Gastaut, J. A., Cassuto, J. P., and Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 Study Group. AIDS, 14(2), 151–155.PubMedGoogle Scholar
  76. Morisky, D. E., Green, L. W., and Levine, D. M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24(1), 67–74.PubMedGoogle Scholar
  77. Murri, R., Ammassari, A., De Luca, A., Cingolani, A., Marconi, P., Wu, A. W., et al. (2001). Self-reported nonadherence with antiretroviral drugs predicts persistent condition. HIV Clinical Trials, 2(4), 323–329.PubMedGoogle Scholar
  78. Nieuwkerk, P., Gisolf, E., Sprangers, M., and Danner, S. (2001). Adherence over 48 weeks in an antiretroviral clinical trial: Variable within patients, affected by toxicities and independently predictive of virological response. Antiviral Therapy, 6(2), 97–103.PubMedGoogle Scholar
  79. Nieuwkerk, P. T., and Oort, F. J. (2005). Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. Journal of Acquired Immune Deficiency Syndromes, 38(4), 445–448.PubMedGoogle Scholar
  80. Nieuwkerk, P. T., Sprangers, M. A., Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Danner, S. A., et al. (2001). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Archives of Internal Medicine, 161(16), 1962–1968.PubMedGoogle Scholar
  81. Oyugi, J. H., Byakika-Tusiime, J., Charlebois, E. D., Kityo, C., Mugerwa, R., Mugyenyi, P., et al. (2004). Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes, 36(5), 1100–1102.PubMedGoogle Scholar
  82. Palepu, A., Horton, N. J., Tibbetts, N., Meli, S., and Samet, J. H. (2004). Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction, 99(3), 361–368.PubMedGoogle Scholar
  83. Paterson, D., Potoski, B., and Capitano, B. (2002). Measurement of adherence to antiretroviral medications. Journal of Acquired Immune Deficiency Syndromes, 31, S103–S106.PubMedGoogle Scholar
  84. Paterson, D., Swindells, S., Mohr, J., Brester, M., Vergis, E., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21–30.PubMedGoogle Scholar
  85. Pinheiro, C. A., de-Carvalho-Leite, J. C., Drachler, M. L., and Silveira, V. L. (2002). Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: A cross-sectional study in Southern Brazil. Brazilian Journal of Medical and Biological Research, 35(10), 1173–1181.PubMedGoogle Scholar
  86. Pradier, C., Carrieri, P., Bentz, L., Spire, B., Dellamonica, P., Moreau, J., et al. (2001). Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDUs. International Journal of STD AIDS, 12(5), 324–328.PubMedGoogle Scholar
  87. Raboud, J. M., Harris, M., Rae, S., and Montaner, J. S. (2002). Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Medicine, 3(2), 118–124.PubMedGoogle Scholar
  88. Rudd, P. (1979). In search of the gold standard for compliance measurement. Archives of Internal Medicine, 139(6), 627–628.PubMedGoogle Scholar
  89. Rudd, P., Ahmed, S., Zachary, V., Barton, C., Bonduelle, D. (1990). Improved compliance measures: Applications in an ambulatory hypertensive drug trial. Clinical Pharmacology and Therapeutics, 48(6), 676–685.PubMedCrossRefGoogle Scholar
  90. Samet, J. H., Sullivan, L. M., Traphagen, E. T., and Ickovics, J. R. (2001). Measuring adherence among HIV-infected persons: Is MEMS consummate technology? AIDS and Behavior, 5(1), 21–30.Google Scholar
  91. Schroder, K. E., Carey, M. P., and Vanable, P. A. (2003). Methodological challenges in research on sexual risk behavior: I. Item content, scaling, and data analytical options. Annals of Behavioral Medicine, 26(2), 76–103.PubMedGoogle Scholar
  92. Schuman, P., Ohmit, E., Cohen, M., Sacks, H., et al. (2001). Prescription of and adherence to antiretroviral therapy among women with AIDS. AIDS and Behavior, 5(4), 371.Google Scholar
  93. Silveira, M. P., Draschler Mde, L., Leite, J. C., Pinheiro, C. A., and da Silveira, V. L. (2002). Predictors of undetectable plasma viral load in HIV-positive adults receiving antiretroviral therapy in southern Brazil. The Brazilian Journal of Infectious Diseases, 6(4), 164–171.PubMedGoogle Scholar
  94. Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., and Moatti, J. P. (2002). Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Social Science and Medicine, 54(10), 1481–1496.PubMedGoogle Scholar
  95. Straka, R. J., Fish, J. T., Benson, S. R., and Suh, J. T. (1997). Patient self-reporting of compliance does not correspond with electronic monitoring: An evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy, 17(1), 126–132.PubMedGoogle Scholar
  96. Trotta, M. P., Ammassari, A., Cozzi-Lepri, A., Zaccarelli, M., Castelli, F., Narciso, P., et al. (2003). Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS, 17(7), 1099–1102.PubMedGoogle Scholar
  97. Turner, B. (2002). Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. The Journal of Infectious Disease, 185(Suppl 2), S143–S151.Google Scholar
  98. Turner, B. J., and Hecht, F. M. (2001). Improving on a coin toss to predict patient adherence to medications. Annals of Internal Medicine, 134(10), 1004–1006.PubMedGoogle Scholar
  99. Vincke, J., Bolton, R. (2002). Therapy adherence and highly active antiretroviral therapy: Comparison of three sources of information. AIDS Patient Care and STDS, 16(10), 487–495.PubMedGoogle Scholar
  100. Wagner, G. J. (2002). Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDS, 16(12), 599–608.PubMedGoogle Scholar
  101. Wagner, G. J., Kanouse, D. E., Koegel, P., and Sullivan, G. (2003). Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care and STDs, 17(4), 179.PubMedGoogle Scholar
  102. Wagner, G., and Miller, L. G. (2004). Is the influence of social desirability on patients’ self-reported adherence overrated? Journal of Acquired Immune Deficiency Syndromes, 35(2), 203–204.PubMedGoogle Scholar
  103. Wagner, J. H., Justice, A. C., Chesney, M., Sinclair, G., Weissman, S., and Rodriguez-Barradas, M. (2001). Patient- and provider-reported adherence: Toward a clinically useful approach to measuring antiretroviral adherence. Journal of Clinical Epidemiology, 54(Suppl 1), S91–S98.PubMedGoogle Scholar
  104. Walsh, J. C., Horne, R., Dalton, M., Burgess, A. P., and Gazzard, B. G. (2001). Reasons for non-adherence to antiretroviral therapy: Patients’ perspectives provide evidence of multiple causes. AIDS Care, 13(6), 709–720.PubMedGoogle Scholar
  105. Walsh, J. C., Mandalia, S., and Gazzard, B. G. (2002). Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS, 16(2), 269–277.PubMedGoogle Scholar
  106. Waterhouse, D. M., Calzone, K. A., Mele, C., Brenner, D. E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology, 11(6), 1189–1197.PubMedGoogle Scholar
  107. Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhema, J., et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 34(3), 281–288.PubMedGoogle Scholar
  108. Wutoh, A. K., Brown, C. M., Kumoji, E. K., Daftary, M. S., Jones, T., Barnes, N. A., et al. (2001). Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. Journal of the National Medical Association, 93(7–8), 243–250.PubMedGoogle Scholar
  109. Wutoh, A., Elekwachi, O., Clarke-Tasker, V., Daftary, M., Powell, N., and Campusano, G. (2003). Assessment and predictors of antiretroviral adherence in older HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 33(2), S106–S114.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Jane M. Simoni
    • 1
  • Ann E. Kurth
    • 2
  • Cynthia R. Pearson
    • 3
  • David W. Pantalone
    • 1
  • Joseph O. Merrill
    • 4
  • Pamela A. Frick
    • 5
  1. 1.Department of PsychologyUniversity of WashingtonSeattleUSA
  2. 2.School of Nursing/CFARUniversity of WashingtonSeattleUSA
  3. 3.School of Public Health & Community MedicineUniversity of WashingtonSeattleUSA
  4. 4.Department of MedicineUniversity of WashingtonSeattleUSA
  5. 5.Department of PharmacyUniversity of WashingtonSeattleUSA

Personalised recommendations